Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.3236
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1413913233069.2798
- FreeCF/Share 14.1116
- PFCF 22.5372
- PE 13.6273
- Debt/Assets 0.1976
- DivYield 0.0245
- ROE 0.6695
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVO | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | NVO | Argus | Buy | Hold | -- | -- | Dec. 8, 2025 |
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
News
Novo Nordisk: This Run Is Just Getting Started
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S stock has jumped 30% since my last coverage. NVO's first-mover advantage in oral GLP-1 positions it well despite rising competition and pricing pressures in obesity and diabetes markets. The company's long-term prospects are bright, and NVO stock appears undervalued.
Read More
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
Published: January 23, 2026 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge.
Read More
Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S is poised for a turnaround in 2026, driven by renewed strategic focus under new CEO Maziar Doustdar. NVO's core strengths in diabetes and obesity, particularly with semaglutide, underpin expectations for double-digit revenue and EPS growth. The launch of oral Wegovy, with superior efficacy and tolerability, positions NVO competitively against Eli Lilly's delayed oral GLP-1 entrant.
Read More
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.
Read More
Novo: Back From The Dead
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk has rebounded over 40% after a sharp 2025 sell-off, driven by renewed optimism for its oral Wegovy launch. Valuation reset, strong technicals, and an underappreciated pipeline make NVO attractive, especially as it transitions from a single-product to a platform company. Upcoming Q4 results are pivotal, with investor focus on oral Wegovy uptake, manufacturing capacity, and margin trajectory amid competitive and political pressures.
Read More
Novo Nordisk expands diabetes cell therapy partnership with Aspect Biosystems
Published: January 20, 2026 by: Reuters
Sentiment: Positive
Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have struck a partnership to develop cell-based treatments for diabetes.
Read More
Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch.
Read More
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch
Published: January 16, 2026 by: CNBC
Sentiment: Positive
Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the launch of the company's new GLP-1 pill for obesity in the U.S. In a Friday note, TD Cowen analysts called it a "solid start" but cautioned that they need to see more data to fully assess what early demand is like for the Wegovy pill.
Read More
Novo Nordisk's Wegovy Weight Loss Shot Approved At Higher Dose in U.K.
Published: January 16, 2026 by: WSJ
Sentiment: Positive
The U.K.'s health regulator approved a higher dose of Novo Nordisk's Wegovy weight-loss drug applicable to patients with a body mass index of at least 30.
Read More
Novo Nordisk obesity pill unlikely to impress early, UBS warns
Published: January 15, 2026 by: Proactive Investors
Sentiment: Neutral
Novo Nordisk (NYSE:NVO) long-awaited obesity pill is unlikely to deliver clear early signals on demand, UBS has warned, even as the Swiss bank raised its price target on the Danish drugmaker's shares by nearly a third. In a note, UBS said that investor focus on initial prescription data for oral Wegovy risked being misplaced, as the figures would not fully capture the early stages of the launch.
Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Published: January 14, 2026 by: CNBC
Sentiment: Neutral
Novo Nordisk CEO Mike Doustdar said 2026 will be the year of "price pressure" as more GLP-1 supply enters the market and pricing deals take effect. Bristol Myers Squibb CEO Chris Boerner said the company has the potential to deliver up to 10 new products by the end of the decade.
Read More
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.
Read More
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs
Published: January 12, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives have captured a significant share of demand for obesity treatments.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight-loss pill
Published: January 09, 2026 by: CNBC
Sentiment: Positive
Amazon said it now offers Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy service. Novo Nordisk began rolling out its first-ever GLP-1 pill in the U.S. earlier this week.
Read More
Amazon Pharmacy offers Novo Nordisk's Wegovy pill
Published: January 09, 2026 by: Reuters
Sentiment: Positive
Amazon Pharmacy said on Friday it now offers Novo Nordisk's Wegovy pill through insurance plans as well as through a cash-pay option.
Read More
Novo Nordisk: My Top Pick For 2026
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk: My Top Pick For 2026
Read More
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
Read More
Novo Nordisk: NVO Stock To $100?
Published: January 06, 2026 by: Forbes
Sentiment: Positive
Novo Nordisk's (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively leverages this first‑mover oral advantage into sustainable volume, pricing authority, and pipeline reliability against Eli Lilly. The stock has increased by approximately 17% in the last month, yet it still remains significantly below its 52‑week peak near 94, suggesting potential for a significant rerating if multiple growth drivers are activated simultaneously.
Read More
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Published: January 05, 2026 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S (NYSE: NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.
Read More
Novo Nordisk launches first oral GLP-1 weight loss pill in the US
Published: January 05, 2026 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) has made its Wegovy pill, the first oral GLP-1 treatment for weight loss, broadly available to patients in the United States. The launch marks a new development in obesity treatment, offering a once-daily pill alternative to weekly injections that have dominated the market.
Read More
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track
Published: January 05, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S launches oral Wegovy in the U.S. at aggressive introductory pricing, aiming to secure early market share and first-mover advantage. NVO faces imminent semaglutide patent expiry in China, triggering a wave of local competition and likely sharp margin compression in 2026. Novo's China revenue, about 6.5% of total, is expected to decline, but U.S. oral GLP-1 ramp should offset regional headwinds.
Read More
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Published: January 05, 2026 by: Market Watch
Sentiment: Positive
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Read More
Exclusive: Novo Nordisk's US public affairs head leaves company
Published: January 05, 2026 by: Reuters
Sentiment: Negative
Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortunes in its top market.
Read More
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
Read More
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
Read More
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win' battle in the U.S. market
Published: January 01, 2026 by: CNBC
Sentiment: Negative
2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China. It follows a difficult year for Novo, marked by volatility and a declining share price.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406